Literature DB >> 10029067

Frequent silencing of the GPC3 gene in ovarian cancer cell lines.

H Lin1, R Huber, D Schlessinger, P J Morin.   

Abstract

GPC3 encodes a glypican integral membrane protein and is mutated in the Simpson-Golabi-Behmel syndrome. Simpson-Golabi-Behmel syndrome, an X-linked condition, is characterized by pre- and postnatal overgrowth as well as by various other abnormalities, including increased risk of embryonal tumors. The GPC3 gene is located at Xq26, a region frequently deleted in advanced ovarian cancers. To determine whether GPC3 is a tumor suppressor in ovarian neoplasia, we studied its expression and mutational status in 13 ovarian cancer cell lines. No mutations were found in GPC3, but its expression was lost in four (31%) of the cell lines analyzed. In an of the cases where GPC3 expression was lost, the GPC3 promoter was hypermethylated, as demonstrated by Southern analysis. Expression of GPC3 was restored by treatment of the cells with the demethylating agent 5-aza-2'-deoxycytidine. A colony-forming assay confirmed that ectopic GPC3 expression inhibited the growth of ovarian cancer cell lines. Our results show that GPC3, a gene involved in the control of organ growth, is frequently inactivated in a subset of ovarian cancers and suggest that it may function as a tumor suppressor in the ovary.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10029067

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

Review 1.  Glypicans: proteoglycans with a surprise.

Authors:  J Filmus; S B Selleck
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

2.  Molecular signatures of X chromosome inactivation and associations with clinical outcomes in epithelial ovarian cancer.

Authors:  Stacey J Winham; Nicholas B Larson; Sebastian M Armasu; Zachary C Fogarty; Melissa C Larson; Brian M McCauley; Chen Wang; Kate Lawrenson; Simon Gayther; Julie M Cunningham; Brooke L Fridley; Ellen L Goode
Journal:  Hum Mol Genet       Date:  2019-04-15       Impact factor: 6.150

3.  Signaling network involved in the GPC3-induced inhibition of breast cancer progression: role of canonical Wnt pathway.

Authors:  Dolores Fernández; Macarena Guereño; María Amparo Lago Huvelle; Magalí Cercato; María Giselle Peters
Journal:  J Cancer Res Clin Oncol       Date:  2018-09-28       Impact factor: 4.553

Review 4.  Proteoglycans in liver cancer.

Authors:  Kornélia Baghy; Péter Tátrai; Eszter Regős; Ilona Kovalszky
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

5.  Expression and significance of tumor-related genes in HCC.

Authors:  Zi-Li Lü; Dian-Zhong Luo; Jian-Ming Wen
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

6.  Glypican 1 stimulates S phase entry and DNA replication in human glioma cells and normal astrocytes.

Authors:  Dianhua Qiao; Kristy Meyer; Andreas Friedl
Journal:  Mol Cell Biol       Date:  2013-09-09       Impact factor: 4.272

7.  Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders.

Authors:  Z W Zhu; H Friess; L Wang; M Abou-Shady; A Zimmermann; A D Lander; M Korc; J Kleeff; M W Büchler
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

8.  Aggressive melanoma cells escape from BMP7-mediated autocrine growth inhibition through coordinated Noggin upregulation.

Authors:  Mei-Yu Hsu; Sherry A Rovinsky; Chiou-Yan Lai; Shadi Qasem; Xiaoming Liu; Joan How; John F Engelhardt; George F Murphy
Journal:  Lab Invest       Date:  2008-06-16       Impact factor: 5.662

9.  Expression of glypican 3 in placental site trophoblastic tumor.

Authors:  Robin J Ou-Yang; Pei Hui; Ximing J Yang; Debra L Zynger
Journal:  Diagn Pathol       Date:  2010-09-25       Impact factor: 2.644

10.  GPC5 is a possible target for the 13q31-q32 amplification detected in lymphoma cell lines.

Authors:  Wei Yu; Jun Inoue; Issei Imoto; Yoshinobu Matsuo; Abraham Karpas; Johji Inazawa
Journal:  J Hum Genet       Date:  2003-04-29       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.